Hiroomi Tada
2021
In 2021, Hiroomi Tada earned a total compensation of $2.5M as Chief Medical Officer at Tyra Biosciences.
Compensation breakdown
| Non-Equity Incentive Plan | $114,735 |
|---|---|
| Option Awards | $1,991,713 |
| Salary | $403,778 |
| Other | $1,135 |
| Total | $2,511,361 |
Tada received $2M in option awards, accounting for 79% of the total pay in 2021.
Tada also received $114.7K in non-equity incentive plan, $403.8K in salary and $1.1K in other compensation.
Rankings
In 2021, Hiroomi Tada's compensation ranked 5,134th out of 12,415 executives tracked by ExecPay. In other words, Tada earned more than 58.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,134 out of 12,415 | 59th |
Division Manufacturing | 2,159 out of 5,501 | 61st |
Major group Chemicals And Allied Products | 928 out of 2,371 | 61st |
Industry group Drugs | 829 out of 2,092 | 60th |
Industry Pharmaceutical Preparations | 593 out of 1,542 | 62nd |
Source: SEC filing on April 28, 2022.
Tada's colleagues
We found three more compensation records of executives who worked with Hiroomi Tada at Tyra Biosciences in 2021.